events SAEs

Related by string. * eventing . EVENTS . EVENT . Events . Eventing . Event . eventer : IN NO EVENT . EVENT GIVING RISE TO . Petersen Events Center . Corporate Event Announcement . event shall AME . shared Events Calendar . SYS CON Events / sae . SAEED . SAES . Saeed . Sae : Iranian negotiator Saeed . Helal Saeed Al Marri . nuclear negotiator Saeed . Saeed Jalili Iran . Saeed Azhar . Saeed Al Maktoum * *

Related by context. All words. (Click for frequent words.) 76 events AEs 73 discontinuations due 71 TEAEs 71 dose limiting toxicities 69 laboratory abnormalities 69 REYATAZ r arm 68 discontinuations 68 Adverse events 67 lopinavir r arm 67 DLTs 67 PREZISTA r 67 R# #mg BID 67 Serious Adverse Events 67 ARCALYST ® 67 receiving INTRON 66 HCV RESPOND 2 66 events TEAEs 66 evaluable subjects 66 ACTEMRA TM 66 neutropenia dehydration dyspnea 66 mcg albinterferon alfa 2b 66 pyrexia mucositis sepsis febrile 66 events MACE 66 FluCAM arm 66 treatment emergent adverse 66 hematologic toxicity 65 CANCIDAS 65 mcg QD 65 SAEs 65 definite stent thrombosis 65 plus OBT 65 HCV SPRINT 65 CIMZIA ™ 65 mg BID 65 RLAI 65 teriflunomide 65 oxycodone CR 65 certolizumab 65 receiving golimumab 64 severe hypersensitivity reactions 64 mCRC acneform rash 64 TYSABRI treated 64 PREZISTA r arm 64 ALT flares 64 adjunctive ABILIFY 64 relapsed MM 64 limiting toxicity 64 adjunctive placebo 64 Serious adverse reactions 64 generalized edema 64 dapagliflozin plus 64 morphometric vertebral fractures 64 FOLPI 64 thromboembolic events 64 dosing cohorts 64 NATRECOR ® 64 achieved ACR# 64 vaccinated PNH patients 64 AEs 64 ribavirin therapy 64 mcg BID 64 severe exacerbations 64 prednisone prednisolone plus 64 plus methotrexate 64 placebo controlled clinical trials 64 Infusion Reactions Severe 64 diarrhea nausea fatigue 63 QTc prolongation 63 mg TID 63 TNF antagonist 63 mcg kg REBETOL 63 intravenous bisphosphonates 63 CYPHER Stent 63 docetaxel chemotherapy 63 patients evaluable 63 PEGINTRON TM 63 adverse reactions observed 63 PRADAXA 63 solifenacin 63 elevated ALT 63 desvenlafaxine succinate 63 elotuzumab 63 8mg/kg 63 TDF FTC 63 severe neutropenia 63 tapentadol ER 63 venlafaxine XR 63 alfa 2a 63 biologic DMARD 63 ATACAND 63 treatment naive genotype 63 ABC/3TC 63 GSK# [001] 62 refractory NSCLC 62 chlorambucil 62 NATRECOR R 62 mg BID dose 62 del 5q MDS 62 headache nasopharyngitis 62 mg ustekinumab 62 ocular adverse 62 FOLFOX4 62 rizatriptan 62 mycophenolate mofetil 62 PREZISTA ritonavir 62 Cariprazine 62 hematological toxicities 62 incidence ≥ 62 placebo controlled studies 62 Postoperative complications 62 hepatotoxicity 62 placebo dexamethasone 62 APTIVUS r 62 oral olanzapine 62 gastrointestinal toxicities 62 Pharmacokinetic parameters 62 EOquin TM phase 62 ARCOXIA 62 Telithromycin 62 Discontinuations due 62 recurrent VTE 62 Torsades de Pointes 62 dose cohort 62 urate lowering therapy 62 antiretroviral naive 62 posaconazole 62 plus dexamethasone 62 stent thromboses 61 tolvaptan 61 linaclotide treated 61 zolmitriptan 61 arterial thromboembolic events 61 virologic breakthrough 61 EXJADE 61 nonvertebral fractures 61 Hepatotoxicity 61 anaphylactoid reactions 61 q#h 61 mcg doses 61 myalgia arthralgia 61 INTRON 61 CIMZIA TM certolizumab pegol 61 RSD# oral 61 budesonide pMDI 61 HBeAg positive patients 61 Treatment emergent adverse 61 adefovir treated 61 PASI scores 61 receiving PEGINTRON 61 peripheral sensory neuropathy 61 hypophosphatemia 61 virologic failure 61 #mg BID [003] 61 LEXIVA r 61 lumiracoxib 61 Hypersensitivity reactions 61 HBeAg negative patients 61 lenalidomide Revlimid R 61 oral diclofenac 61 CIMZIA TM 61 salmeterol HFA MDI 61 abacavir lamivudine 61 efalizumab 61 active comparator 61 mg kg dose 61 ARB telmisartan 61 receiving XGEVA 61 cytogenetic response 61 #mg BID [001] 61 galiximab 61 dosage regimens 61 PegIFN RBV 61 μg doses 61 moderate renal impairment 61 MAGE A3 ASCI 61 severe renal impairment 61 mg administered orally 61 hypoglycaemic episodes 61 Immune reconstitution syndrome 61 experienced hypomagnesemia 61 dose cohorts 61 LEVAQUIN ® 61 acneform rash 61 Stent thrombosis 61 Toxicities 61 Raptiva r 61 Febrile neutropenia 61 comparator arm 61 Hematologic toxicity 61 underwent CABG 61 hypoglycemic events 61 valacyclovir 61 RRMS patients 61 Peg IFN 61 EDEMA3 61 adalimumab 61 riociguat 61 #mg QD [002] 61 INSPIRE Trial Phase III 61 oral rivaroxaban 61 EMPHASIS HF trial 61 HBeAg positive 61 pegylated interferon alfa 2a 61 ug dose 61 REMICADE ® 60 genotypic resistance 60 receiving VICTRELIS 60 Ophena TM 60 refractory gout 60 lopinavir r 60 mg QD 60 infliximab monotherapy 60 treatment emergent AEs 60 INVEGA ® 60 placebo controlled trials 60 FOLFIRI 60 hematologic adverse 60 demonstrated antitumor activity 60 TORISEL 60 cytopenias 60 patients receiving ERBITUX 60 maximally tolerated dose 60 metastatic RCC 60 transaminase elevations 60 BENICAR HCT 60 deep venous thromboses 60 plus prednisone prednisolone 60 INVANZ 60 mg q#h 60 heavily pretreated patients 60 risperidone Risperdal 60 ZYVOX 60 mg RDEA# 60 multicenter Phase III 60 nadroparin 60 dose regimens 60 pharmacokinetic characteristics 60 β blockers 60 recurrent glioblastoma multiforme 60 evaluable patients 60 MCyR 60 FOLPI regimen 60 HBeAg seroconversion 60 undetectable HBV DNA 60 BARACLUDE ® 60 dosing cohort 60 treatment naïve genotype 60 placebo controlled clinical 60 Teriflunomide 60 VaD 60 COPD exacerbation 60 ertapenem 60 evaluating tivozanib 60 Engerix B 60 RE LY ® 60 postmenopausal osteoporotic women 60 febrile neutropenia 60 eosinophilic asthma 60 HMG CoA reductase inhibitors 60 octreotide LAR 60 fluvastatin 60 highly emetogenic 60 hypoglycemic episodes 60 ritonavir boosted atazanavir 60 lymphopenia 60 Dermatologic toxicities 60 maximal doses 60 interferon alfa 2b 60 tipranavir r 60 primary hypercholesterolemia 60 symptomatic aortic stenosis 60 naïve HCV 60 splenectomized patients 60 MERLIN TIMI 60 mg/m2 dose 60 Peripheral edema 60 TMC# r 60 virologic response 60 telaprevir dosing 60 renal toxicity 60 AA Amyloidosis 60 hematological adverse 60 cerebrovascular events 60 plus MTX 60 ZACTIMA 60 EDARBI 60 MYCAMINE 60 evaluable 60 salmeterol fluticasone 60 CTA# Injection 60 gout flare 60 prolonged QT interval 60 receiving VELCADE 60 LEXIVA 59 discontinued Viread 59 Baseline characteristics 59 nucleoside naive 59 dose escalation phase 59 nadolol 59 Thrombotic events 59 AGILECT R 59 diabetic neuropathic pain 59 EURIDIS 59 Viread Emtriva 59 antiretroviral naïve 59 myocardial infarctions 59 briakinumab 59 prednisone prednisolone 59 ritonavir boosted 59 RECORD1 59 Peginterferon Alfa 2a 59 hepatic failure 59 bosentan 59 unresectable HCC 59 gastrointestinal adverse reactions 59 syncopal 59 certolizumab pegol 59 VELCADE melphalan 59 azathioprine monotherapy 59 bezafibrate 59 stage IIIb IV 59 oxycodone IR 59 INFERGEN 59 receiving ISENTRESS 59 Discontinuations 59 AML MDS 59 hypersensitivity reaction 59 HIV HCV coinfected 59 venous thromboembolic events 59 leukopenia 59 ORENCIA ® 59 AVOREN 59 intraocular inflammation 59 ACTEMRA 59 ß blockers 59 ipsilateral stroke 59 efavirenz EFV 59 hematological toxicity 59 advanced adenomas 59 DAPT 59 dalteparin 59 #mg dose [003] 59 darunavir ritonavir 59 locoregional recurrence 59 statin monotherapy 59 EDEMA3 trial 59 adverse reactions incidence 59 Reversible Posterior Leukoencephalopathy Syndrome 59 alfuzosin 59 hypomagnesemia 59 flutamide 59 receiving prophylactic anticoagulation 59 Primary endpoints 59 pomalidomide 59 hepatic dysfunction 59 Serious ocular 59 Renal impairment 59 Afatinib 59 hypersensitivity reactions 59 rosuvastatin Crestor 59 SSRI SNRI 59 plus COPEGUS 59 doxorubicin cyclophosphamide 59 remission CR 59 acute HAE attacks 59 invasive aspergillosis 59 mg/m2/day 59 myelosuppression 59 CAMMS# 59 #mg/day [002] 59 lacosamide 59 bone marrow reticulin deposition 59 aldosterone antagonist 59 seroconverted 59 relapsed myeloma 59 neutropenia thrombocytopenia 59 APTIVUS ritonavir 59 pegylated interferon alpha 59 fluoxetine paroxetine 59 #mg q8h 59 cardiac toxicity 59 metastatic HRPC 59 thromboembolic complications 59 monoamine oxidase inhibitors MAOIs 59 Bezielle 59 symptomatic pulmonary embolism 59 TNF antagonists 59 FOLFOX4 alone 59 endoscopic remission 59 NOMID 59 Hypertensive adverse reactions 59 adverse reactions occurring 59 Mg Usa 59 Non inferiority 59 INVEGA ® SUSTENNA ® 59 relapsed refractory multiple myeloma 59 PREZISTA rtv 59 interferon gamma 1b 59 rFVIIa 59 mcg Albuferon 59 mGluR5 NAM 59 fatigue asthenia 59 reactogenicity 59 humanized interleukin 6 59 double blinded placebo 59 Perforomist Inhalation Solution 59 PRADAXA #mg 59 ACR# response 59 decompensated liver disease 59 leucopenia 59 thromboembolic 59 mg/# h 59 haloperidol Haldol 59 VIIBRYD 59 paclitaxel eluting stents 59 diarrhea nausea vomiting 59 thromboembolism 59 symptomatic VTE 59 zidovudine lamivudine 59 chronic GVHD 59 sustained virologic response 59 XIENCE V PROMUS Stent 58 PEG INTRON R 58 adalimumab Humira 58 Treatment discontinuations due 58 TAXUS VI 58 intracerebral hemorrhages 58 intracerebral hemorrhage 58 ximelagatran 58 #mg dose [001] 58 tolerability profiles 58 clinically meaningful differences 58 DEB# 58 â ‰ ¥ 58 thrombotic events 58 anthracycline taxane 58 vaccinees 58 delayed CINV 58 COPD exacerbations 58 divalproex sodium 58 amoxicillin clavulanate 58 hypercalcemia 58 evaluating mipomersen 58 peginterferon 58 blinded randomized placebo controlled 58 EMEND 58 hepatic impairment 58 liver transplant recipients 58 INCB# [003] 58 vismodegib 58 symptomatic BPH 58 stable angina 58 benazepril 58 somatostatin analog 58 #mg doses [002] 58 haematologic 58 conjunctival hyperemia 58 Folfox 58 severe hepatomegaly 58 pericardial effusions 58 mucocutaneous reactions 58 NNT = 58 visilizumab 58 recurrent malignant glioma 58 adverse reactions 58 paroxetine Paxil 58 ARIMIDEX 58 Pegasys ® 58 unstable angina pectoris 58 ribavirin RBV 58 #mg/day [001] 58 QT interval prolongation 58 ALT elevations 58 systemic absorption 58 achieved CCyR 58 BRIM2 58 androgen suppression 58 CYT# potent vascular disrupting 58 REMINYL ® 58 DOXIL 58 mg eq 58 Paxil paroxetine 58 corticosteroid therapy 58 echinacea tablets 58 EDSS scores 58 Traficet EN 58 MACCE 58 plus prednisone 58 oral antidiabetes 58 Tarceva TM 58 NOLVADEX 58 NYHA Class II 58 Lamictal XR 58 Randomized Double blind 58 Syndrome RLS 58 IFN alfa 58 OADs 58 evaluating Xcytrin 58 latrepirdine 58 KRAS mutations occur 58 QTc 58 moderately emetogenic 58 MULTAQ 58 RSV hospitalizations 58 events thrombocytopenia neutropenia 58 Angioedema 58 nab paclitaxel 58 SVR# 58 Mg Uk 58 6R BH4 58 timepoints 58 asthma exacerbation 58 Phase IIIb clinical 58 bevirimat Study 58 enalapril 58 BRIM3 58 bazedoxifene conjugated estrogens 58 anemia neutropenia 58 4mg/kg 58 baseline HbA1c 58 metastatic GIST 58 hypercholesterolemic patients 58 perioperatively 58 neutropaenia 58 ARIXTRA 58 QT prolongation 58 Tindamax R 58 fingolimod 58 CYPHER R Sirolimus eluting 58 Lipitor #mg 58 #mg/m# [002] 58 RAPTIVA 58 STELARA ® 58 Erythropoietic therapies may 58 superficial edema 58 aldosterone antagonists 58 somnolence dizziness 58 dyskinesia PD LID 58 dasatinib Sprycel ® 58 myopathy rhabdomyolysis 58 aflibercept VEGF Trap 58 delayed onset CINV 58 GnRH agonists 58 viral kinetic 58 landmark ATHENA 58 R rilonacept Injection 58 phase III isavuconazole 58 pegylated interferon alfa 2b 58 insulin detemir 58 nonhematologic adverse reactions 58 urate lowering 58 ORENCIA 58 dosed orally 58 REYATAZ ritonavir 58 lipid lowering agents 58 mitoxantrone plus 58 opioid naive 58 Hypotension 58 oral hypoglycemic agent 58 Elitek 58 mapatumumab 58 oxymorphone ER 58 anaphylactic reactions bronchospasm 58 peg IFN 58 tocilizumab 58 Adalimumab 58 atazanavir ritonavir 58 Index CDAI 58 nonmetastatic prostate cancer 58 venlafaxine ER 58 nephrotoxicity 58 microgram kg 58 acetaminophen codeine 58 docetaxel Taxotere ® 58 abatacept 58 estramustine 58 venlafaxine Effexor 58 oral vancomycin 58 intra articular injection 58 non splenectomized 58 Pemetrexed 58 nonrandomized 58 CCyR 58 mCi kg 58 nondiabetic patients 58 neurologic complications 58 pharmacokinetic interactions 58 headache abdominal pain 58 μg dose 58 R ribavirin USP 58 ascending doses 58 PEGINTRON REBETOL combination 57 plus gemcitabine 57 Kidney toxicity nephrotoxicity 57 SPIRIT FIRST 57 accompanying electrolyte abnormalities 57 levetiracetam 57 balsalazide 57 adverse reactions ≥ 57 acute gout flares 57 cholinesterase inhibitor 57 NEUPOGEN 57 postoperative mortality 57 ZOMIG 57 Emtriva Viread 57 atorvastatin Lipitor 57 null responder HCV 57 hemoptysis 57 dermatologic reactions 57 lenalidomide dexamethasone 57 ancrod 57 MADRS score 57 JANUVIA 57 achieved PASI 57 ticlopidine 57 mitoxantrone 57 Median survival 57 unfractionated heparin UFH 57 reinfarction 57 subtrochanteric 57 TNF antagonist therapy 57 severe rotavirus gastroenteritis 57 huC# DM4 57 HBeAg negative 57 Serious AEs 57 angioneurotic edema 57 stage IIIB 57 CR CRu 57 Acneform rash occurred 57 AVANDIA 57 mcg dose 57 APTIVUS 57 REYATAZ r 57 candidemia 57 recurrent GBM 57 FASLODEX 57 dizziness nausea diarrhea 57 homozygous familial hypercholesterolemia 57 intracranial hemorrhage ICH 57 Relapsed Refractory Multiple Myeloma 57 dacarbazine 57 tenofovir emtricitabine 57 mg m² 57 ZIAGEN 57 Immune Reconstitution Syndrome 57 pancytopenia 57 adefovir 57 sertraline Zoloft 57 ALVESCO 57 XIENCE V demonstrated 57 KETEK 57 rosuvastatin #mg 57 RoACTEMRA 57 DAS# scores 57 Amrubicin 57 neutropenia febrile neutropenia 57 non valvular atrial 57 Adverse reactions 57 neuropsychiatric symptoms 57 GetGoal Phase III 57 mcg kg 57 heavily pretreated 57 Certolizumab 57 Lactic acidosis 57 phase IIIb 57 mild renal insufficiency 57 splenectomized 57 sunitinib malate 57 beta blocker therapy 57 PEGylated interferon beta 1a 57 phase IIb study 57 clazosentan 57 tamsulosin 57 PREMPRO 57 renal impairment 57 cisplatin gemcitabine 57 FFNS 57 lumbar spine BMD 57 Hycamtin ® 57 HIV seronegative 57 malignancy HCM 57 COPEGUS 57 antiepileptic medications 57 recurrent venous thromboembolism 57 FOLFOX 57 revascularizations 57 receptor tyrosine kinase inhibitor 57 metformin monotherapy 57 CIPN 57 dose dose escalation 57 rimonabant #mg/day 57 CrCl 57 Randomized Phase 57 PROMUS Element Stent 57 pheochromocytoma 57 telaprevir dosed 57 #mg QD [001] 57 moderate hepatic impairment 57 extrapyramidal symptoms 57 acyclovir valacyclovir 57 hyperphenylalaninemia HPA due 57 CONCERTA 57 chills fever headache 57 LATUDA 57 HAM D# scores 57 COU AA 57 q8h 57 non hematological toxicities 57 mg dose 57 neurologic outcomes 57 Seliciclib 57 reduce serum phosphate 57 methotrexate monotherapy 57 placebo PBO 57 didanosine associated 57 MEVACOR 57 limiting toxicity DLT 57 mg Pycnogenol 57 tapentadol IR 57 alicaforsen enema 57 TTF Therapy 57 β blocker 57 intravenous bolus 57 Platinol ® cisplatin 57 clozapine Clozaril 57 IIIa inhibitor 57 sorafenib Nexavar 57 ExTRACT TIMI 57 acyclovir Lauriad R 57 CR nPR 57 antiarrhythmic drugs 57 sustained ventricular tachycardia 57 VFEND 57 MEND CABG 57 gemifloxacin 57 locoregional 57 azathioprine 57 paliperidone ER 57 tacrolimus ointment 57 mcg linaclotide 57 Pharmacokinetics PK 57 rimonabant #mg 57 tumor lysis syndrome 57 spontaneous preterm delivery 57 danazol 57 arterial thromboembolic 57 valdecoxib 57 antidepressants fluoxetine 57 administered concomitantly 57 ritonavir boosted lopinavir 57 QTc interval 57 symptomatic hyponatremia 57 primary Restless Legs 57 lomitapide 57 #mg/m# [001] 57 Oral Fingolimod 57 DASISION 57 idraparinux 57 undergone radical prostatectomy 57 peginterferon alfa 57 ABSORB trial 57 iniparib BSI 57 saline placebo 57 aripiprazole Abilify 57 BYSTOLIC 57 Aztreonam lysine 57 clinically meaningful improvement 57 EFFEXOR XR 57 infusion reactions 57 BoNTA 57 AVELOX 57 AEGR 57 mg qd 57 subgroup analyzes 56 forodesine 56 postintervention 56 pulmonary toxicity 56 postoperative chemotherapy 56 vertebral fracture 56 arterial embolism 56 timepoint 56 FDA defined valvulopathy 56 R lenalidomide 56 fulminant hepatitis 56 histologically confirmed 56 corticosteroid dose 56 peginterferon alfa 2a 56 ziprasidone Geodon 56 maximal tolerated 56 neutropenic fever 56 MARINOL ® 56 peginterferon alfa 2b 56 anemia hemoglobin 56 LOVENOX R 56 leukopenia pancytopenia thrombocytopenia 56 KRAS mutant tumors 56 hypokalemia 56 hepatorenal syndrome 56 venous thromboembolic disease 56 Secondary endpoints 56 Viread Emtriva Sustiva 56 clinically meaningful improvements 56 nicardipine 56 Q2W 56 OAB symptoms 56 pCR 56 inhospital 56 nonfatal stroke 56 poor metabolizers 56 O PPDS 56 prior chemotherapy regimens 56 plus ribavirin 56 neutropenic sepsis 56 baseline FEV 56 Tolerability 56 TG MV 56 interferon ribavirin 56 DU #b 56 Flu Cy 56 CRESTOR #mg 56 nasopharyngitis headache 56 TMP SMX 56 multicenter Phase 56 endophthalmitis 56 lymphocytosis 56 elevated transaminases 56 AIR CF1 56 REVLIMID ® 56 phase IIb clinical 56 leukotriene receptor antagonists 56 revascularization procedures 56 hypersensitivity reactions eg anaphylaxis 56 ICD shocks 56 cilengitide 56 paroxetine Seroxat 56 MenACWY CRM 56 achieved statistical significance 56 atherothrombotic events 56 ONGLYZA 56 eltrombopag 56 ischemic cardiomyopathy 56 sustained virological response 56 ketoconazole 56 clodronate 56 weekly subcutaneous injections 56 endometrial hyperplasia 56 detectable HCV RNA 56 HCV genotype 56 bendamustine 56 ketoacidosis hyperosmolar coma 56 irbesartan 56 intermittent dosing 56 Exacerbations 56 ACAPODENE 56 Lupuzor ™ 56 mCRC patients 56 HPA axis suppression 56 periprocedural 56 pharmacodynamic parameters 56 concomitant medications 56 TELINTRA 56 potentially hepatotoxic 56 tiotropium 56 cardiac tamponade cerebral edema 56 microbiologically evaluable 56 HORIZONS AMI trial 56 hsCRP levels 56 bovine thrombin 56 virological response 56 Cimzia ® 56 bolus dose 56 oral alendronate 56 sotalol 56 VP# [004] 56 trastuzumab emtansine T DM1 56 acromegalic patients 56 tirofiban 56 rash pruritus nausea 56 oral antidiabetic medication 56 daily Infergen 56 LAMICTAL 56 ROZEREM TM 56 lintuzumab SGN 56 Alkeran 56 prospectively defined 56 phase Ib 56 onset atrial fibrillation 56 TO AVOID PREGNANCY WHILE 56 secondary efficacy endpoint 56 anakinra 56 hypersensitivity allergic reactions 56 interferon alfa 2a 56 Budesonide foam crofelemer 56 GAMMAGARD 56 TAXUS p value 56 REBETOL therapy 56 nonfatal MI 56 Hematologic 56 underwent resection 56 Carotid Revascularization Endarterectomy vs. 56 widespread sickouts 56 risperidone olanzapine 56 pericardial effusion 56 aprepitant 56 recurrent genital herpes 56 #mg dosing group 56 microbiological eradication 56 carboplatin paclitaxel 56 renal flares 56 AZILECT 56 intravenous RSD# 56 lamotrigine 56 atorvastatin #mg 56 Edge STudy 56 paroxysmal AF 56 cobiprostone 56 fatal hemorrhagic 56 angioedema 56 montelukast 56 fluticasone salmeterol 56 REYATAZ 56 zoledronic acid Reclast 56 unique alkylating agent 56 fatal anaphylactic 56 paroxetine sertraline 56 oxcarbazepine 56 HGS ETR1 mapatumumab 56 tipranavir ritonavir 56 seroprotection 56 canakinumab 56 IRLS score 56 composite endpoint 56 MADIT CRT trial 56 randomized Phase III 56 Phase Ib clinical 56 piperacillin tazobactam 56 randomized multicenter Phase III 56 Aflibercept 56 progressive PsA 56 albiglutide 56 cytologically confirmed 56 ALN HPN 56 3TC lamivudine Epivir 56 hyperbilirubinemia 56 olanzapine risperidone 56 coadministration 56 dapsone 56 ISENTRESS 56 Meets Primary Endpoint 56 levosimendan 56 gastrointestinal perforation 56 antiepileptic drug 56 aged ≥ 56 ascending dose 56 Gemzar ® 56 pegylated liposomal doxorubicin 56 melphalan prednisone 56 serum HCV RNA 56 memantine HCl 56 eosinophilic pneumonia 56 Anaphylactic reactions 56 SUSTENNA TM 56 administered subcutaneously 56 coinfected patients 56 cervical spine fractures 56 intravascular hemolysis 56 chronic HCV infection 56 nonsevere 56 tolerability profile 56 nasopharyngitis 56 clopidogrel Plavix 56 PEG INTRON 56 NMDA receptor antagonists 56 antiepileptics 56 log# copies mL 56 LymphoStat B belimumab 56 PARTNER Trial 56 recurrent ischemia 56 low dose cytarabine 56 tamoxifen Nolvadex ® 56 multicenter placebo controlled 56 crizotinib PF # 56 Myelosuppression 56 endometriosis ovarian cysts 56 basal bolus regimen 56 ventricular tachyarrhythmia 56 CLL SLL 56 papillary renal cell carcinoma 56 INTEGRILIN R 56 NPH insulin 56 mg kg cohorts 56 telcagepant 56 gadobutrol 56 dopamine partial agonist 56 oral allopurinol 56 5-FU/LV 56 ROCKET AF 56 fallopian tube cancers 56 CIMZIA R

Back to home page